Vemurafenib, a BRAF kinase inhibitor, has been shown to be effective in <i>BRAF</i> V600E mutation-positive malignancies, such as NSCLC and melanoma, as well as in several case reports of Erdheim-Chester disease. This evidence concerns the gene BRAF and non-small cell lung carcinoma.